Ultragenyx Pharma, Kyowa Kirin Report Topline Phase 3 Study Results For Crysvita For Treatment To Oral Phosphate, Active Vitamin D In Children With X-Linked Hypophosphatemia: Met Primary Endpoint
Benzinga Newsdesk